ZA988009B - Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy. - Google Patents

Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy.

Info

Publication number
ZA988009B
ZA988009B ZA9808009A ZA988009A ZA988009B ZA 988009 B ZA988009 B ZA 988009B ZA 9808009 A ZA9808009 A ZA 9808009A ZA 988009 A ZA988009 A ZA 988009A ZA 988009 B ZA988009 B ZA 988009B
Authority
ZA
South Africa
Prior art keywords
administering
methods
receptor antagonist
dopamine agonist
ampa receptor
Prior art date
Application number
ZA9808009A
Other languages
English (en)
Inventor
Bertrand Leo Chenard
John Timothy Greenamyre
Frank Samuel Menniti
Jr Willard Mckowan Welch
Original Assignee
Pfizer Prod Inc
John Timothy Greenamyre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, John Timothy Greenamyre filed Critical Pfizer Prod Inc
Publication of ZA988009B publication Critical patent/ZA988009B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9808009A 1997-09-05 1998-09-02 Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy. ZA988009B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5796597P 1997-09-05 1997-09-05

Publications (1)

Publication Number Publication Date
ZA988009B true ZA988009B (en) 2000-03-22

Family

ID=22013812

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9808009A ZA988009B (en) 1997-09-05 1998-09-02 Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy.

Country Status (11)

Country Link
US (1) US20010034345A1 (fr)
EP (1) EP0900567A3 (fr)
JP (1) JP3547624B2 (fr)
KR (1) KR100457756B1 (fr)
AU (1) AU8319398A (fr)
CA (1) CA2246560C (fr)
HU (1) HUP9802022A2 (fr)
IL (1) IL125953A0 (fr)
NZ (1) NZ331636A (fr)
TW (1) TW490304B (fr)
ZA (1) ZA988009B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20005049U1 (de) * 2000-03-20 2000-05-18 Dewert Antriebs- und Systemtechnik GmbH & Co KG, 32278 Kirchlengern Elektromotorische Antriebseinheit
FR2857594B1 (fr) * 2003-07-17 2005-09-16 Servier Lab Composition pharmaceutique pour l'administration par voie nasale de piribedil
EP1604654A1 (fr) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement des dyskynesies
WO2006109876A1 (fr) * 2005-04-08 2006-10-19 Eisai R & D Management Co., Ltd. Agent pour traiter un mouvement involontaire
EP2010184B1 (fr) * 2006-04-06 2013-01-09 Nupathe Inc. Implants destines au traitement d'etats associes a la dopamine
EP2079739A2 (fr) 2006-10-04 2009-07-22 Pfizer Products Inc. Dérivés de pyrido[4,3-d]pyrimidin-4(3h)-one utilisés en tant qu'antagonistes du récepteur calcique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
WO1992013535A1 (fr) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Quinazolones substituees a activite anticonvulsivante
PT101004B (pt) * 1991-10-26 1999-10-29 Schering Ag Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem
KR100375155B1 (ko) * 1996-05-15 2003-08-19 화이자 인코포레이티드 신규한2,3-이치환된-4(3에이치)-퀴나졸리논

Also Published As

Publication number Publication date
CA2246560A1 (fr) 1999-03-05
US20010034345A1 (en) 2001-10-25
HU9802022D0 (en) 1998-10-28
KR19990029528A (ko) 1999-04-26
CA2246560C (fr) 2002-12-17
TW490304B (en) 2002-06-11
EP0900567A2 (fr) 1999-03-10
HUP9802022A2 (hu) 1999-05-28
KR100457756B1 (ko) 2005-04-14
EP0900567A3 (fr) 2001-05-02
IL125953A0 (en) 1999-04-11
NZ331636A (en) 2000-08-25
AU8319398A (en) 1999-03-18
JP3547624B2 (ja) 2004-07-28
JPH11139991A (ja) 1999-05-25

Similar Documents

Publication Publication Date Title
ZA988139B (en) Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy.
AU2666901A (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
NZ503233A (en) Synergistic analgesic combination of opioid analgesic and COX-2 inhibitor
HK1064614A1 (en) Use of methylnaltrexone to treat immune suppression
AU7490700A (en) Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
EA200500726A1 (ru) 4-тетразолил-4-фенилпиперидин производные для лечения боли
PL353854A1 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
HUP0200189A3 (en) Transdermal therapeutic system with nicotine
ZA988009B (en) Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy.
IL143385A0 (en) 5ht1 antagonists for antidepressant therapy
WO2001007028A3 (fr) Utilisation d'antagonistes de recepteurs de retinoides dans le traitement du cancer de la prostate
AU7788500A (en) Use of substance p antagonists for influencing the circadian timing system
AU2003273250A1 (en) Triazaspiro compounds useful for treating or preventing pain
GB9811312D0 (en) Method of treatment with an angiotensin II antagonist
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
IL127518A (en) Substituted heterocyclic benzocycloalkenes, their preparation and pharmaceutical compositions having an analgesic effect
WO2000076500A3 (fr) Compound for use as a medicament for treatment of disorders involving bronchocontraction
AU2002300534A1 (en) Methods of Administering an AMPA Receptor Antagonist to Treat Dyskinesias Associated with Dopamine Agonist Therapy
WO2002039996A3 (fr) Therapie combinee contre des tumeurs comprenant du phosphate d'estramustine et des agonistes ou antagonistes de lh-rh
AU8553898A (en) Use of 2,3-benzodiazepine derivatives for the preparation of pharmaceutical compositions to treat diseases connected with the endogenous opioid system
DE60102481D1 (en) Purinriboside als antiarrhythmika
EP1508337A3 (fr) Utilisations relatives aux antagonistes et agonistes vis-a-vis du récepteur de la famille Eph pour le traitement des troubles vasculaires
AU8680998A (en) Method for preventing or treating erectile dysfunction by administering an endothelin antagonist